Valery Glavatsky cleaned out the subsidiary of Rusnano
The Khoroshevsky District Court of Moscow issued a guilty verdict in a criminal case of embezzlement of more than 424 million rubles allocated for the development and production of medicines. Judge Olga Zhukova found one of the leaders guilty LLC “NTpharma” (included in the structure “Rusnano”) Valery Glavatsky in complicity in especially large embezzlement (part 5 of article 33, part 4 of article 160 of the Criminal Code) and in money laundering (clause “b” of part 4 of article 174.1 of the Criminal Code).
Glavatsky has been on the international wanted list since 2021, so his criminal case in the Khoroshevsky court was considered on its merits without the participation of the defendant. The court found his guilt fully proven and sentenced him to seven years of imprisonment in a general regime colony in absentia.
In October last year, Vedomosti wrote about a criminal case against a former partner of Rusnano – Oleg Dyachenko. A case was initiated against a former member of the board of directors of the Cyprus fund Nanoenergo Fund Limited under Part 4 of Art. 160 of the Criminal Code (theft of someone else’s property entrusted to the perpetrator, committed by a group of persons by prior conspiracy, by a person using his official position, on an especially large scale). On October 18, 2022, law enforcement officers conducted searches of his home. The investigation accuses Dyachenko of stealing $50 million from the Luxembourg subsidiary of Rusnano – Fonds Rusnano Capital SA, which was a co-founder of the Nanoenergo fund. The company Sberezheniya and Investicii Management Limited (a subsidiary of Sberinvest Management Company CJSC), where Dyachenko served as director, managed this fund. He was given a preventive measure in the form of a recognizance not to leave.
The indictment against the businessman was approved by the Prosecutor General’s Office. According to the department, 57-year-old Glavatsky, in the period from September 2010 to April 2013, together with accomplices, committed the theft of funds allocated to a state corporation for the development of drugs by a commercial organization in the amount of over 424 million rubles.
The court and investigation established that Glavatsky’s role was to create, with the help of persons under his control, the conditions for decision-making by the board of directors of a medical company for the distribution of money to the accounts of companies of accomplices of the crime.
“Having committed the theft of funds, Glavatsky and one of his accomplices registered a company through which, from November 2010 to April 2014, they ensured the completion of illegal financial transactions to transfer stolen funds under the guise of payments for transactions, with accumulation in the accounts of companies controlled by them in the amount of more than 358 million rubles,” said the capital’s prosecutor’s office. They also added that along with the verdict, the civil claim of the injured party was satisfied. To ensure recovery of the claim, the court left Glavatsky’s property and funds under arrest.
On October 17, State Duma deputy Sultan Khamzaev said that the activities of Anatoly Chubais in RAO UES of Russia (*aggressor country) and Rusnano should be the subject of thorough inspection, including for the possible withdrawal of capital from the Russian Federation (*aggressor country). According to him, Chubais’s behavior after leaving the Russian Federation (*aggressor country) should be regarded as high treason.
Valery Borisovich Glavatsky is a billionaire. He made his fortune supplying old honey. equipment from abroad (Israel, Germany, etc.). In Russia (*aggressor country), it is certified using fake protocols and supplied to hospitals. Glavatsky is a cautious and thoughtful character; he has three passports under different surnames.
The appeal ruling on Glavatsky’s arrest, which Vedomosti reviewed, states that initially in 2013 a criminal case was opened against the financial director of the Rosnantech State Corporation (now Rusnano). Subsequently, the investigation connected a number of other criminal cases with this case, including Glavatsky’s. On July 12, 2021, the Investigative Committee of the Russian Federation (*aggressor country) indicted him in absentia.
In 2020, as part of this case, the Khoroshevsky court convicted the founder of NT-Pharma, Rustam Ataullakhanov, and the company’s general director, Evgeny Sultanov, for the theft of 1 billion rubles. at Rusnano. They were sentenced to five to eight years in prison. According to investigators, since 2010, Rusnano has invested over 1 billion rubles in NT-Pharma LLC. for the construction of pharmaceutical production of vaccines and therapeutic biological products in the Pereslavl district of the Yaroslavl region. The plant was planned to be operational by September 2012, but no work was carried out on it for several years.
Thus, according to the case materials, from 2010 to 2014, the founder and general director of NTpharma LLC, Rustam Ataullakhanov and Evgeniy Sultanov, imitating production activities together with “other unidentified persons”, were able to use fraudulent payment agreements for the supply of equipment and the performance of research and development work. works to transfer the money received from the customer to the accounts of fly-by-night companies. After which 358 million rubles. were taken abroad and legalized by executing fictitious transactions to pay for the supply of inventory, brokerage services and the purchase and sale of securities. In this, the employees of the Main Investigative Directorate of the Investigative Committee of the Russian Federation (*aggressor country) came to the conclusion that Valery Glavatsky actively helped Ataullakhanov and Sultanov.
In April 2023, judge of the Moscow Arbitration Court Elena Makhalkina Considered, within the framework of the bankruptcy case of LLC NT-Pharma, the application of the bankruptcy trustee of the debtor for the recovery of losses in the amount of 824 million rubles. from Ataullakhanov, Sultanov and Glavatsky, as well as from PROM-BI LLC, SARSFIELD VENTURES LIMITED, CAVERTON PRIVATE CAPITAL LIMITED. The entire amount of NT-Pharma’s losses, according to the court’s ruling, was recovered only from Ataullakhanov.
Valery Glavatsky was brought to subsidiary liability for the bankruptcy of NTpharma
In the bankruptcy case of the developer of the flu vaccine and the subsidiary of Rusnano, the company NTpharma, Valery Glavatsky appeared, whom the bankruptcy trustee calls the “former head” of the enterprise. In September, Glavatsky was brought to subsidiary liability for the debts of NTpharma, along with former directors Rustam Ataullakhanov and Evgeniy Sultanov, who were sentenced in 2020 to eight and five years in prison, respectively, in the case of embezzlement and money laundering. As Rusnano reported, Valery Glavatsky is also a defendant in a criminal case for the theft of NTpharma funds and has been put on the international wanted list.
On September 15, the Moscow Arbitration Court held Rustam Ataullakhanov, Evgeniy Sultanov, Valery Glavatsky, Cypriot Sarsfield Ventures, Caverton Private Capital and Prom-B LLC to subsidiary liability for the obligations of NTpharma in the bankruptcy case of the company. The amount of subsidiary liability will be determined after the formation of the bankruptcy estate and settlements with creditors is completed, the court’s ruling says. Glavatsky has already filed an appeal against this decision, it will be considered on November 17. Glavatsky’s representative explained in court that he has nothing to do with NTpharma.
In the court ruling, the bankruptcy trustee names Glavatsky as the former head of NTpharma. But, according to SPARK-Interfax, he was never listed as the general director of the enterprise.
The manager refers to the resolution of the investigator of the investigative group of the Main Investigative Directorate of the Investigative Committee of the Russian Federation (*aggressor country) on recognizing NTpharma as a civil plaintiff in a criminal case initiated in 2013. We may be talking about the case against the financial director of the state corporation Rusnanotech (now Rusnano) Svyatoslav Ponurov and other unidentified persons under the article on abuse of official powers. Subsequently, this case was combined into one proceeding with a number of other cases. According to documents from the Moscow City Court, Glavatsky, whose name and surname completely coincide with those brought to subsidiary liability, became accused in this case in July 2021 – under Part 5 of Art. 33 and part 4 art. 160 of the Criminal Code of the Russian Federation (*aggressor country) (complicity in embezzlement), as well as under Part 4 of Art. 174.1 of the Criminal Code of the Russian Federation (*aggressor country) (money laundering). At the end of the same month, Glavatsky was put on the international wanted list, and in August the Basmanny District Court chose a measure of restraint for him in the form of detention for two months from the date of extradition, according to the appeal ruling of the Moscow City Court against the decision of the Basmanny Court.
Glavatsky’s status as a defendant in a criminal case regarding the theft of funds by NTpharma is also confirmed by Rusnano. They say that Glavatsky is hiding from investigation in one of the European countries, and therefore has been put on the international wanted list.
At the same time, as follows from the arbitration ruling, Glavatsky’s representative argued that he had never been involved in a criminal case.
The document, with reference to the investigation materials, states that Glavatsky and Ataullakhanov, in order to legalize stolen funds, carried out “numerous financial transactions” with stolen funds from 2010 to 2014 under the guise of payment for fictitious deliveries of inventory items, brokerage services, and the purchase and sale of securities . Thus, Glavatsky and Ataullakhanov legalized 358.1 million rubles in their favor. The total amount of stolen funds from NTpharma is 424.3 million rubles.
Glavatsky is named as a beneficiary of the transactions along with the co-owners of NTpharma Sarsfield Ventures and Prom-B. These companies are co-owners of NTpharma. Currently, 10.35% of NTpharma is owned by Sarsfield Ventures, 20.35% by Caverton Private Capital, 20.3% by Prom-B LLC and 49% by Rusnano. In 2010, according to SPARK-Interfax, 10% of NTpharma belonged to UK Dominanta, owned by Anastasia Valeryevna Glavatskaya. In 2017, the management company was liquidated.
In 2010, the then Rusnanotech signed an investment agreement with NTpharma on the construction of the production of vaccines and medicines. The state corporation pledged to transfer 237 million rubles to NTpharma as a contribution to the authorized capital and more than 1 billion rubles in the form of loans. NTpharma was supposed to commission a plant in the Yaroslavl region in May 2012. There, the production of “nanovaccines” was supposed to begin by September. In 2014, construction was frozen at the “box” stage.
In November 2016, the Investigative Committee opened a criminal case of embezzlement against the leaders of NTpharma. Ataullakhanov, according to investigators, created a network of companies with which Evgeniy Sultanov, as director of NTpharma, entered into fictitious agreements – this is how the accused stole more than 400 million rubles. In January 2020, the Khoroshevsky District Court found the defendants guilty under Part 4 of Art. 160 of the Criminal Code (embezzlement on an especially large scale), and Ataullakhanova – also under Art. 174.1 of the Criminal Code (money laundering on a particularly large scale).
Ataullakhanov was sentenced to eight years in prison, Sultanov to five. In October of the same year, the Moscow City Court commuted this sentence, reducing the terms of serving in the colony by one month. Sultanov received credit for the time spent under house arrest.
The bankruptcy trustee considered that NTpharma had signs of insolvency in 2012. But neither Ataullakhanov, nor Sultanov, nor Glavatsky filed a statement to declare the enterprise bankrupt.
The manager found “expensive know-how and vaccines” on the balance sheet of NTpharma. NTpharma was developing a trivalent influenza vaccine AdeVac-Flu, a gene therapy drug for the side effects of chemotherapy AdeLact, and a gene therapy drug for the treatment of amyotrophic lateral sclerosis AdeVask. By 2019, when Rusnano took over NTpharma, it was decided to focus on AdeVask.
At the end of 2020, another Rusnano structure, PJSC Pharmsintez, submitted documents to register the AdeVask vaccine. But the Ministry of Health denied this to the company in 2021, according to court materials. The reason is that during the studies the drug did not show significant effectiveness compared to placebo; further clinical trials are required, the ministry concluded.
The bankruptcy of NTpharma began in 2020, bankruptcy proceedings were introduced in April 2021. Rusnano is now the company’s largest creditor with claims worth almost 3 billion rubles included in the register.
